| abstract |
In the present application, a composition containing a compound or a pharmaceutically acceptable salt thereof, which is metabolized to monomethyl fumarate, having a specific pharmacokinetic parameter, and a method for treating a neurodegenerative disease, including multiple sclerosis, , Wherein the composition contains dimethyl fumarate, wherein the total amount of dimethyl fumarate in the composition ranges from about 43 wt% to about 95 wt%. |